Momenta pharmaceuticals, inc. (MNTA)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]
Net Income (Loss) Available to Common Stockholders, Basic

-290,055

-176,061

-88,096

-21,003

-83,313

-98,600

-108,408

-58,648

180,356

37,290

-64,012

Adjustments to reconcile net loss to net cash used in operating activities:
In-process research and development expense related to acquisition of sialylation technology assets

-

-

-

-

-

-

-

-

4,500

-

-

Depreciation and amortization of property and equipment

11,610

9,917

8,023

7,600

7,594

7,637

7,108

6,419

4,137

4,361

4,470

Impairment of equipment

0

3,608

0

0

-

-

-

-

-

-

-

Share-based compensation expense

22,430

21,222

16,127

18,322

11,440

13,594

12,822

13,712

11,138

10,840

10,755

Amortization of premium on investments

1,728

438

-167

-595

-1,383

-2,162

-3,575

-3,288

-1,677

-893

57

Amortization of intangibles

1,153

1,153

1,153

1,529

1,061

1,061

1,061

1,061

1,378

299

326

Impairment of equity investment

-

-

-

-

-

-

244

-

-

-

-

Gain on disposal of assets

750

-510

-61

0

0

-

-23

19

-238

-102

-114

Gain (Loss) on Termination of Lease

13,720

0

0

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Collaboration receivable

-3,358

-3,677

-55,194

49,057

10,849

-6,172

2,284

-17,360

-26,314

54,485

-455

Unbilled revenue

-

-

-

-

-

-

2,613

-1,965

-2,500

515

2,378

Prepaid expenses and other current assets

4,227

-573

2,098

1,128

14

64

-1,552

2,406

754

100

476

Restricted cash

-

-

-

-

-59

0

748

-2,471

15,722

-

-

Other long-term assets

-4,225

703

-1,229

1,692

92

0

-

389

389

-

-12

Accounts payable

4,831

-1,158

7,446

-1,032

-3,380

1,126

2,727

-1,129

315

169

-1,353

Accrued expenses

43,413

-6,229

-6,253

2,043

14,151

-1,099

1,806

510

33

2,984

-630

Accrued restructuring

-3,201

3,235

0

0

-

-

-

-

-

-

-

Collaboration liabilities

-598

-4,537

-23,637

32,895

0

0

-

-

-

-

-

Deferred revenue

-3,855

-33,438

-5,015

16,649

-9,015

3,282

-3,979

27,931

-2,149

-2,850

-1,450

Deferred rent

-

-

-

-

-

-

-

-

-

-

70

Lease incentive

0

5,860

4,051

0

0

-

-

-

-

-

-

Other liabilities

8,429

15,182

-66

-449

-58

22

-18

482

9

-47

-1,000

Other long-term liabilities

13,883

2,037

2,629

3,724

-482

-461

300

517

144

2

-

Purchase of equity investment

-

-

-

-

-

-

-

400

-

-

-

Acquisition of sialylation technology assets

-

-

-

-

-

-

-

-

4,500

-

-

Milestone payment related to Parivid for developed technology

-

-

-

-

-

-

-

-

6,664

-

-

Net cash used in operating activities

-204,802

-155,590

-29,085

8,989

-71,515

-65,168

-86,832

8,999

213,725

-1,057

-55,294

Cash Flows from Investing Activities:
Purchases of property and equipment

1,776

9,019

17,127

5,609

4,068

8,360

9,450

15,491

8,699

1,671

1,654

Proceeds from disposal of equipment

3,148

1,447

267

0

0

-

-

-

-

-

-

Purchases of marketable securities

274,581

202,525

524,888

360,008

405,673

111,809

229,969

515,088

551,272

90,765

110,194

Proceeds from maturities of marketable securities

315,174

308,178

420,669

445,665

245,907

195,342

294,183

523,572

302,415

111,501

89,575

Proceeds from sales of marketable securities

-

-

-

-

-

-

3,822

-

-

-

-

Net cash used in investing activities

41,965

98,081

-121,079

80,048

-163,834

75,173

58,586

-7,407

-268,720

19,065

-22,273

Cash Flows from Financing Activities:
Proceeds from public offering of common stock, net of issuance costs

-

-

-

0

148,439

0

-

-

-

57,085

46,766

Net proceeds from issuance of common stock

244,480

217,786

64,090

0

64,503

18,305

-

-

-

-

-

Proceeds from issuance of common stock under stock plans

16,489

29,272

10,258

2,407

24,567

3,273

5,022

2,153

5,546

6,735

569

Net cash provided by financing activities

260,969

247,058

74,348

1,341

235,461

21,578

5,022

2,153

3,559

60,739

44,431

Repurchase of common stock pursuant to share surrender

-

-

-

1,066

2,048

0

-

-

-

-

-

Payments on financed leasehold improvements

-

-

-

-

-

-

-

-

258

737

687

Principal payments on capital lease obligations

-

-

-

-

-

-

-

-

1,729

2,344

2,200

Principal payments on line of credit

-

-

-

-

-

-

-

-

-

-

17

Net decrease in cash, cash equivalents and restricted cash

98,132

189,549

-75,816

90,378

112

31,583

-23,224

3,745

-51,436

78,747

-33,136

Non-Cash Activities:
Common shares issued to Parivid to settle milestone payment

-

-

-

3,190

0

0

-

-

-

-

-

Purchases of property and equipment included in accounts payable and accrued expenses

1,051

43

1,228

935

0

0

-

-

-

-

-

Financing fees in accounts payable

275

0

0

-

-

-

-

-

-

-

-

Receivable due from broker for issuance of common stock under ATM facility

-

-

-

-

0

-

-

-

-

-

-

Receivable due from stock option exercises

0

0

93

0

-

-

-

-

-

-

-

Impact from adoption of ASUs

-

-

-

-

0

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

91

329

570

Issuance of common stock for payment of Parivid milestone

-

-

-

-

-

-

-

-

-

-

1,000

Accounting Standards Update 2016-09
Impact from adoption of ASUs

0

0

783

0

-

-

-

-

-

-

-

Accounting Standards Update 2014-09
Impact from adoption of ASUs

0

5,511

0

0

-

-

-

-

-

-

-